Immutep Stock Plummets 82.6%, Sparking Fraud Investigations

Edgen Stock

·Mar 30 2026, 04:46

Share to

Share to

Copy link

Key Takeaways

Immutep Limited is under investigation for potential securities fraud after its stock collapsed following the abrupt discontinuation of a key clinical trial. The probes, initiated by multiple law firms, focus on whether the company misled investors with positive statements just weeks before announcing the trial's failure, which wiped out over 80% of its market value.

Immutep's stock collapsed 82.6% to close at $0.48 per share on March 13, 2026, after the company halted its TACTI-004 Phase III cancer trial.
The discontinuation was recommended for futility, directly contradicting a January 30, 2026, filing that cited "strong operational progress" for the same trial.
Law firms including Levi & Korsinsky and Rosen Law Firm are now preparing class-action lawsuits alleging the company issued materially misleading information to investors.

Immutep Stock Collapses 82.6% After Phase III Trial Halt

Immutep Limited's (NASDAQ: IMMP) stock price disintegrated on March 13, 2026, after the company announced the discontinuation of its TACTI-004 Phase III study. The trial was evaluating its lead drug candidate, eftilagimod alfa, for first-line non-small cell lung cancer. The decision came after an Independent Data Monitoring Committee (IDMC) reviewed the data and recommended halting the study for futility.

The market reaction was immediate and severe. Immutep's American Depositary Receipts (ADRs) plummeted by $2.28, an 82.6% decline, to close the day at just $0.48 per share. The halt means patient enrollment will stop, and the company will begin an orderly wind-down of the study, erasing a key potential value driver for the biotechnology firm.

Law Firms Allege Fraud Over Contradictory Statements

Following the stock's collapse, multiple shareholder rights law firms, including Levi & Korsinsky and Rosen Law Firm, have launched investigations into Immutep for potential securities fraud. The probes center on a 6-K form the company filed with the SEC on January 30, 2026, just six weeks before the trial was terminated.

In that filing, Immutep had assured investors that the TACTI-004 trial was "on track for the first quarter of CY2026" and cited "strong operational progress." These positive statements stand in stark contrast to the subsequent futility recommendation from the IDMC. Law firms allege this discrepancy suggests the company may have issued materially misleading business information, which artificially inflated the stock price and resulted in significant losses for investors who purchased shares based on the optimistic outlook.